[Urothelial carcinoma after treatment with cyclophosphamide. Review of the literature and presentation of our caseload].
Cyclophosphamide has been used since 1958 in the treatment of various malignant tumours and certain systemic diseases, toxicity to the urothelium, frequently causing haemorrhagic cystitis and less often urothelial carcinomas, being one of its most notorious side effects--some 60 urothelial carcinoma cases have been published following therapy with cyclophosphamide since 1971. The present paper is a contribution of two new cases and its raises the need of paying special attention to urinary manifestations as well as narrowing the cooperation between the physicians which prescribe cyclophosphamide and the urologist, in order to make an appropriate follow-up and management of the patient.
Ramada Benlloch
F J
FJ
Servicio de Urología, Hospital General Universitario de Valencia.
Gonzalvo Pérez
V
V
Blasco Alfonso
E
E
Donderis Guastavino
C
C
Navalón Verdejo
P
P
Zaragozá Orts
J
J
D002295:Carcinoma, Transitional Cell / Q000139:chemically induced*; D003520:Cyclophosphamide / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*
D003520:Cyclophosphamide
Carcinoma de urotelio tras tratamiento con ciclofosfamida. Revisión de la literatura y aportación de nuestra casuística.